tau imaging news adds a staging tool to Alzheimer's workups without changing the diagnosis itself. For younger-onset families, the practical news is clearer measurement of tau tangles to guide timing, referrals, and trial questions.
Tau PET is a brain scan that uses an injected tracer to show tau tangles, twisted proteins tied to Alzheimer's damage. According to the FDA approval notice from Lantheus, the agency approved Tauklarify, florquinitau F18 injection, on Aug. 14, 2026 for adults with cognitive impairment being evaluated for Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did regulators approve?
- Why does sensitivity matter?
- Does a tau scan diagnose Alzheimer's alone?
- What should younger-onset families ask next?
What did regulators approve?
Tauklarify is an F18-labeled tracer for tau PET in adults with cognitive impairment undergoing Alzheimer's evaluation. Its role is to help identify tau neurofibrillary-tangle pathology in the brain.
The same Lantheus notice describes it as a complement to amyloid PET and other tools. It helps clinicians place a patient within the Alzheimer's process, not replace the broader workup.
Why does sensitivity matter?
A more sensitive tau tracer can reveal early buildup that older tracers miss. That matters when symptoms are mild, unclear, or early in life.
In a multicenter head-to-head study of 682 people, MK-6240, now Tauklarify, found tau more than twice as often in cognitively unimpaired people than approved flortaucipir, as reported by NeurologyLive's coverage of the Lancet study. The same comparison found stronger discrimination of Alzheimer's-related impairment, with AUC 0.93 versus 0.86, plus strong agreement between readers for positive-versus-negative reads.
Does a tau scan diagnose Alzheimer's alone?
No. Alzheimer's is defined biologically by Core 1 markers such as amyloid PET, specified spinal-fluid ratios, or accurate blood tests such as p-tau217. According to the Alzheimer's Association criteria page, tau PET is generally a Core 2 marker for staging and prognosis, not a standalone diagnosis.
Label limits also matter for families weighing a scan. According to Practical Neurology's label summary, safety and effectiveness are not established for non-Alzheimer's tau diseases, performance may be lower at earlier stages, a negative scan does not rule out tangles, and a positive scan does not prove histologically confirmed tangles. The report is available in Practical Neurology's approval summary.
What should younger-onset families ask next?
Younger-onset families face symptoms before age 65, sometimes in the 30s or 40s with deterministic APP, PSEN1, or PSEN2 mutations, where precise staging and trial eligibility matter most. For them, tau PET is best viewed as one piece beside amyloid testing, spinal-fluid or blood markers, MRI, family history, and genetic counseling. Bring a short checklist to the visit: Lantheus said broader commercial availability was still being assessed at approval, so call the imaging center before making travel plans.
- Is tau PET available locally, or only at selected centers?
- How do radiation, medications, and other health conditions affect scheduling?
- What will insurance cover, and what is the cash cost?
- How will the result change care, monitoring, support planning, or trial referral?
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
